Significant decreases in well differentiated and distant stage prostate cancers might suggest effects of PSA testing in the post-PSA-era; however, prostate cancer screening alone cannot explain the changes in prostate cancer trends. This evidence concerns the gene KLK3 and prostate carcinoma.